CV Participants
Elaine Dzierzak studied biology at the University of Illlinois, (USA) and received her PhD in Biology from Yale University where she studied the molecular basis for immunoglobulin specificity and regulated expression. She did her postdoctoral training an the Whitehead Institute for Biomedical Research (MIT) and was the first to demonstrate the expression of a retrovially transduced therapeutic gene in hematopoietic cells after bone marrow stem cell transplantation. She started her own research laboratory at the National Institute for Medical Research (London), initiating studies on the embryonic origins of hematopoietic stem cells. During this time her laboratory changed the long-held textbook dogma of the yolk sac origins of the adult hematopoietic system and have shown that the first adult-type HSCs are autonomously generated in the intrabody portion of the mammalian embryo, the aorta-gonads-mesonephros (AGM) region. In 1996 she moved her research group to Erasmus University, Dept. of Cell Biology and Genetics where she is a Professor of Developmental Biology and Co-director and founder of the Master of Science Program in Molecular Medicine at Erasmus University Medical Center Rotterdam. She has recently been awarded with a Verneiuwingsimpuls VICI subsidy. She aims to identify the molecules involved in the generation and expansion of hematopoietic stem cells with long term goals to improve clinical cell replacement therapies for blood-related genetic diseases and leukemias.
Pandolfi et al. (1995) Nature Genetics, 11:40-44.
Medvinsky and Dzierzak (1996) Cell 86, 897-906.
Sanchez et al. (1996) Immunity, 5:513-525.
Miles et al. (1997) Development,1245:537-547.
De Bruijn et al. (2000) EMBO J. 19, 2465-2474.
De Bruijn et al. (2000) Blood, 15, 2902-2904.
Cai et al. (2000) Immunity, 13, 423-431.
Oostendorp et al. (2002) Blood, 99, 1183-1189.
North et al. (2002) Immunity, 16, 661-672.
De Bruijn et al. (2002) Immunity 16, 673-684.
Frank Grosveld studied biochemistry at the University of Amsterdam and obtained a PhD from McGill University (1976). After two postdoctoral periods (Zurich, C. Weissmann and London, R. Flavell), he became Head of the division (1981) of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, UK. In 1993 he accepted the Chair of Cell Biology at the Erasmus University Rotterdam. Mechanisms of gene regulation and epigenetic phenomena have been the primary focus of his research. His group has carried out pioneering work in many aspects of gene regulation from concluding that DNA methylation inhibits gene expression via an indirect mechanism, to the first description of an LCR or visualizing the primary transcription process in the nucleus. His group has filed a considerable number of patents and has closely collaborated with industrial partners. He is and has been on the advisory board of a number of companies and is co-founder of four start-ups, including a gene therapy based company (Therexsys) and a genetics based company (Minos Biosystems Biosystems).
Milot et al. (1996) Cell 87: 105-114.
Dillon et al. (1997) Mol Cell 1: 131-137.
Marin et al. (1997) Cell 89: 619-628.
Van Leeuwen et al. (1998) Science 279: 242-247.
Calzolari et al. (1999) EMBO J 18:949-958.
McMorrow et al. (2000) EMBO J 19:4986-4996.
Whyatt et al. (2000) Nature 406:519-524.
Akhmanova et al. (2001) Cell 23:923-935.
De Krom et al., (2002) Molec. Cell 9 1319-26
Hoogenraad et al., (2002) Nat Genet. 32:116-127.
Anton Grootegoed studied biology at Nijmegen University, and obtained a PhD from Erasmus University Rotterdam based on his thesis work on hormonal control of spermatogenesis (1978). Following a post-doc period at City of Hope (Duarte, CA, USA, with Susumu Ohno) he continued to study gametogenesis in Rotterdam. In 1990 he became professor of biochemical endocrinology and accepted the chair of the Department of Endocrinology and Reproduction; within Erasmus MC this is now named the Department of Reproduction and Development, integrated into the Medical Genetics Cluster. The research of his department is focused on gametogenesis and sex differentiation in mammalian species, including work on cancers of the reproductive system (prostate cancer and endometrium cancer). His group performed the first cloning of the anti-müllerian hormone receptor, which was followed by the discovery that anti-müllerian hormone is involved in control of ovarian follicle development. Other studies address chromatin structure and gene expression in gametogenesis, also in the context of development of new methods for non-hormonal male contraception, in close collaboration with an industrial partner. Since 1986, he is advisor of the WHO (basic science projects male contraception). At Erasmus MC he is co-director and founder of the Master of Science Program in Molecular Medicine.
Baarends et al. (1994) Development 120:189-197
Hendriksen et al. (1995) Dev Biology 170:730-733
Brüggenwirth et al. (1997) Am J Hu Genet 61:1067-77
Baarends et al. (1999) Dev Biology 207:322-33
Emmen et al. (2000) Endocrinology 141:846-849
Durlinger et al. (2001) Endocrinology 142:4891-4899
Roest et al. (1996) Cell 86:799-810
Ng et al. (2002) Mol Cell Biol 22:1233-1245
Baarends et al. (2003) Mol Cell Biol 23:1151-1162
Oosterhoff et al. (2003) Oncogene in press
Dies Meijer received his PhD degree from the Erasmus University Rotterdam in 1992 for his studies into transcription factors controlling embryonic and spermatogenic stem cell development. He obtained postdoctoral training at the National Institute for Medical Research, Mill Hill London where he joined the laboratory of Dr Frank Grosveld to study gene structural elements defining the regulatory domains of gene activity during development. In 1994 he moved back to the department of Cell Biology and Genetics at the Erasmus University Rotterdam where he initiated and continues studies on glial cell development and myelination in the peripheral nervous system. He is a participant in a European Community Network on peripheral nerve development and differentiation. His studies are currently mapping the genetic cascade required in Schwann cell generation in the mouse embryo and is also involved in studies linking these genes to peripheral nerve diseases in human.
Jaegle et al. (1996) Science, 273, 507-510.
Blanchard et al. (1996) J Neurosci Res, 46, 630-640.
Zwart et al. (1996) Mech Dev, 54, 185-194.
Levavasseur et al. (1998) Mech Dev, 74, 89-98.
Jaegle, Meijer (1998) Microsc Res Tech, 41, 372-378.
Mandemakers et al. (2000) EMBO J, 19, 2992-3003.
Ghislain et al. (2002) Development, 129, 155-166.
Ilia et al. (2002) Am J Psychiatry, 159, 1174-1182.
Ghazvini et al. (2002) EMBO J, 21, 4612-4620.
Jaegle et al. (2003) Genes and Development, In press.
Hans Clevers received his MD and PhD degrees in 1984 and 1985 and worked at
Harvard University (Boston) for four years. In 1991, he became professor and chairman of the
department of Immunology at the University Medical Center in Utrecht. In 2002, he will become
co-director of NIOB. Clevers is a member of EMBO and of the Royal Netherlands Academy of Sciences.
His major research interest is the role of the Wnt cascade in development and cancer of the intestine.
His major research findings include 1) the key role of Tcf factors in the Wnt signaling cascade in worms,
flies, frogs and mammals, 2) the key role of Tcf4 in the maintenance of stem cells
in the gut epithelium and 3) the key role of deregulated Tcf4 in the malignant transformation
of the gut epithelium, the first step forward colon cancer.
Schilham et al. (1996) Nature, 380: 711-714.
Molenaar et al. (1996) Cell, 86, 391-399.
Korinek et al. (1997) Science, 275: 1784-1787.
van de Wetering et al. (1997) Cell, 88, 789-799.
Korinek et al. (1998) Nat Genet 19(4): 379?383.
Roose et al. (1998) Nature 395(6702): 608-612.
Roose et al. (1999) Science 285: 1923-1926
Korswagen et al. (2002) Nature 406: 527-532.
Battle et al. (2002) Cell 111:251-263.
Van de Wetering et al. (2002) Cell 111:241-250.
Frits Meijlink studied biochemistry at the University of Amsterdam and obtained a PhD from the University Groningen (1983) where he studied structure and function of estradiol-regulated genes. During his postdoctoral period in the group of Inder M. Verma in San Diego he worked on function and regulation of the c-fos gene. Since 1985 he works in the Hubrecht Laboratory on function and regulation of homeobox genes. Initially he worked on Hox genes, and then focused on a group of paired-related homeobox genes. His research group demonstrated overlapping functions of these ‘aristaless-like’ genes in development of the limbs and craniofacial primordia and established links between the aristaless like genes and hedgehog signalling in craniofacial development. His research interest includes functions of this group of genes in cardiovascular development.
Ten Berge et al. (1998) Development 125:3831-3842
Ten Berge:et al.:(1998) Dev.Biol. 199:11-25
Meijlink:et al. (1999) Int.J.Dev.Biol. 43:651-63
Beverdam et al. (2001) Development 128:3975-3986
Beverdam etal (2001) Mech.Dev. 107:163-67
Ten Berge et al. (2001) Development 128:2929-2938
Te Welscher:P. (2002) Science 298:827-830
White:P. et al (2003) J.Invest.Dermatol. 120:135-144
Brouwer et al. (2003) Mech.Dev. 120:241-252.
Oosterveen et al. (2003) EMBO J. 22:262-269
Jacqueline Deschamps studied Biological Chemistry at the University of Brussels, and got her Ph.D in yeast genetics in the Department of Microbiology at this University in 1979. After a first postdoc in molecular biology on Bovine Leukemia Virus in A. Burny’s laboratory in Brussels, and a second postdoc on the regulation of the c-fos proto-oncogene in I. Verma’s laboratory in San Diego, she obtained the position of research group leader at the Hubrecht laboratory in Utrecht in 1987. She has been working since then on the genetic basis of mouse embryonic development, focusing on the role of transcription factor encoding gene families in antero-posterior development. Her group is one of the few that contributed data on the regulation of Hox genes during early embryogenesis.
Charite et al. (1994) Cell 78:4(8 26);589?601.
Charite et al. (1995) Dev. Biol. 171, 294-305.
Charite et al. (1998) Development, 125, 4349-4358.
van den Akker et al. (1999) Mech. of Dev., 89, 103-114.
van den Akker et al. (2001) Development, 128, 1911-1921.
Roelen et al. (2002) Mech. of Dev., in press.
van den Akker et al. (2002 Development, 129, 2181-93.
Zeller R., Deschamps J. (2002) Nature, 420, 138-139
Oosterveen et al., (2003) EMBO J., 22, 1-8.
Voncken et al., (2003) Proc. Natl. Acad. Sci In press.
Christine Mummery studied physics at the University of Nottingham, UK and obtained a PhD at the University of London. She joined the Hubrecht Laboratory in 1978 to study neuroblastoma cells in the group of S.W.de Laat. She introduced embryonal carcinoma and embryonic stem cells into the laboratory in 1984 and used them for research on the function of growth factors in growth control and early differentiation. Recent focus of her group has been on the transforming growth factor b superfamily in cardiovascular development using mutant mice and embryonic stem cells as models for a human vascular disease caused by mutations in TGFb receptors. In 2000, she introduced human embryonic stem cells into the Netherlands and has identified selected mouse embryonic tissues as sources of inductive signals for their differentiation. Embryonic and adult stem cells are currently being compared for their ability to contribute to cardiovascular repair in mouse models (supported by ESI and ICIN). She is on the scientific advisory board of ESI. In 2002, she became ICIN Professor of Developmental Biology of the Heart at the University Medical Centre, Utrecht.
Baudoin et al., Genes Dev. 12:1202-1216 (1998)
Goumans et al., Development 126:3473-3483 (1999)
Zwijsen et al., Dev.Dyn. 214:141-151 (1999)
Kester et al, Dev. Dyn.218: 563-572 (2000)
Zwijsen et al., Dev.Dyn. 218:663-670 (2000)
Larsson et al, EMBO J. 20:1663-1673.(2001)
Vaes et al, J.Bone Min.Res. in press (2002)
Cachaco et al, Development (2003) In press.
C d Sousa Lopes et al, Mech.Dev. (2003) In press
Mummery et al, Circulation (2003) in press
Riccardo Fodde studied biology and molecular genetics at the University of Pavia, Italy. His PhD work on hemoglobins and haptoglobins has been carried out at the Dept. of Human Genetics of the University of Leiden, and has led to the chararcteriation of the spectrum of mutations leading to haemoglobinopatheis in The Netherlands. In 1990 he started his post-doctoral work on the molecular genetic basis of colorectal cancer within the same department. As a fellow of the Royal Dutch Academy of Science (KNAW) he visited the laboratory of prof. Raju Kucherlapati at the A. Einstein College of Medicine in New York, where he developed the first targeted mouse model for intestinal tumorigenesis. In 2001, he has been full professor of Cancer Genetics at the Center for Human & Clinical Genetics of the Leiden University Medical Center (LUMC). His group has contributed to the elucidation of the molecular basis of hereditary colorectal cancer in man, developed a large number of pre-clinical mose models for colorectal carcinogenesis, and characteried novel functional aspects of the APC tumor suppressor gene. Most recently, the focus of his research has been centered around the role of APC and b-catenin in embryonic and stem cell differentiation. Since 2003 he is professor of Experimental Pathology at the Josephine Nefkens Institute of the Erasmus Medical Center in Rotterdam.
Fodde et al. PNAS USA 91:8969-8973 (1994).
Wijnen et al. N Engl J Med 339:511-8 (1998).
Wijnen et al. Nat Genet 20:326-328 (1998).
Smits et al. Genes Dev 13:1309-1321 (1999).
Wijnen et al. Nat Genet 23:142-144 (1999).
Smits et al. Gastroenterology 119:1045-53. (2000).
Fodde et al. Nat Rev Cancer 1:55-67 (2001).
Fodde et al. Nat Cell Biol 3:433-8 (2001).
Fodde and Smits. Science 298761-763 (2002).
Kielman, et al. Nat Genet 32:594-605 (2002).
Peter Verrijzer studied biochemistry at Utrecht University, The Netherlands and obtained his PhD from the same university (1992) where he studied eukaryotic DNA replication in the laboratory of P. van der Vliet. During his postdoctoral period in the group of Robert Tjian at the University of California at Berkeley he started his work on the basic mechanisms of gene regulation in animal cells. He was involved in the cloning of subunits of the general transcription factor TFIID, its reconstitution and discovered that selective TAF subunits within TFIID determine core promoter selectivity. In 1996 he joined the Imperial Cancer Research Fund in London as a group leader to study the role of chromatin and epigenetic processes in the regulation of development and cell proliferation. In 1999 he became a full professor of Molecular and Cell Biology at the Leiden University Medical Centre. His group was the first to show functional selectivity among chromatin remodeling factors and contributed to understanding several aspects of the molecular mechanisms by which transcriptional regulators function.
Verrijzer et al. (1994) Science 264, 933-941.
Chen et al., (1994) Cell 79, 93-105.
Verrijzer et al., (1995) Cell 81, 1115-1125.
Kaufmann et al., (1996) Genes Dev. 10, 873-886.
Katsani et al. (1999) EMBO J. 18, 698-708.
Chalkley and Verrijzer (1999) EMBO J. 18, 4835-4845.
Kal et al., Genes Dev. (2000) 14: 1058-1071.
Verrijzer et al. Science (2001) 293: 2010-2011.
Katsani et al., Genes Dev. (2001) 15: 2197-2202.
Mahmoudi et al., EMBO J. (2002) 21: 1775-1781.
Maarten van Lohuizen studied biology at the University of Amsterdam. His PhD work (1992, supervisor A. Berns & P. Borst) demonstrated the power of using retroviruses in genetic screens to identify cooperating oncogenes in cancer-predisposed mice. After a postdoctoral period (San Franscisco, I. Herskowitz) he joined the Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, to start his own research group (1995). His group has made important contributions on the functional analysis of epigenetic gene silencing mechanisms by Polycomb-group protein complexes, which play crucial roles in controlling development, differentiation and cell proliferation and when deregulated contribute to cancer formation. Recently, his group has also developed genome wide genetic screens in cell-based assays and in cancer-prone mice to identify new genes that contribute to cancer and classify them in functional groups/signaling pathways. His group consists of approximately 15 post-docs, graduate students and technicians. In 2001 he became Professor at Utrecht University Medical School and in 2002 was appointed as head of the Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam.
Alkema et al. (1995) Nature 374, 724-7
Alkema et al. (1997) Genes Dev. 11, 226-40
Van Lohuizen et al. (1998) Mol. Cell Biol. 18, 3572-9
Bel et al.(1998) Development 125, 3543-51
Jacobs et al. (1999) Nature 397, 164-8
Jacobs et al. (1999) Genes Dev. 13, 2678-90
Voncken et al. (1999) J. Cell Sci. 112, 4627-39
Hanson et al. (1999) Proc. Natl. Acad. Sci., 96, 14372-8
Jacobs et al. (2000) Nat Genet. 26, 291-99.
Lund et al.(2002) Nat Genet. 32, 160-5.
|
